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IMMUNOBIOLOGY
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The molecular mechanisms that underlie
T-cell quiescence are poorly understood.
In the present study, we report a primary
immunodeficiency phenotype associated
with MST1 deficiency and primarily char-
acterized by a progressive loss of naive
T cells. The in vivo consequences include
recurrent bacterial and viral infections
and autoimmune manifestations. MST1-
deficient T cells poorly expressed the
transcription factor FOXO1, the IL-7 recep-
tor, and BCL2. Conversely, FAS expres-
sion and the FAS-mediating apoptotic
pathway were up-regulated. These abnor-
malities suggest that increased cell death
of naive and proliferating T cells is the
main mechanism underlying this novel
immunodeficiency. Our results character-
ize a new mechanism in primary T-cell
immunodeficiencies and highlight a role
of the MST1/FOXO1 pathway in control-
ling the death of human naive T cells.
(Blood. 2012;119(15):3458-3468)
Introduction
The study of human T-cell primary immunodeficiencies has
enabled the molecular characterization of many diseases caused by
Mendelian inheritance of mutated genes1-4 and has revealed the
function of key molecules in T-cell biology. SCIDs are character-
ized by complete lack of T-cell development and, in some
conditions, developmental blocks on other lymphoid lineages.1,2
Several mechanisms can leads to faulty T-cell differentiation, such
as the premature death of progenitor cells and impaired c-
dependent cytokine signaling, VDJ recombination, or pre-TCR
signaling.1 In other forms of T-cell primary immunodeficiency,
TCR-mediated T-cell activation is defective but T-cell differentia-
tion is partially or fully preserved. The latter variously include
deficiencies in DOCK8, ZAP-70, ITK, ORA1, and STIM-1, all of
which are involved in the signaling cascade downstream of the
TCR, and in molecules involved in the NFB pathway, such as
NEMO and IKB.2,5,6 These conditions are collectively referred to
as combined immunodeficiencies (CIDs), because the functional
consequences also include defective Ab production.
The molecular signatures of many more T-cell immunodefi-
ciency phenotypes have yet to be identified. In the present study,
we describe a new form of human CID observed in 4 patients from
2 families that is primarily characterized by a dramatically reduced
pool of circulating naive T cells and impaired in vitro survival of
the T-lymphocyte population. These patients were shown to carry
homozygous mutations in the serine-threonine protein kinase
4 (STK4) gene, coding for the ubiquitously expressed mammalian
sterile 20-like protein MST1.
Methods
Case reports
Patient F1P1 was born to a consanguineous family of Turkish origin (see
Figure 1A). Since the age of 2, he had suffered from recurrent skin and
lower respiratory tract infections caused by Streptococcus pneumoniae and
Haemophilus influenzae, leading to bronchiectasis, recurrent perioral
herpes simplex infections with positive anti–HSV1-2 IgG titer, Varicella
zoster virus (VZV) infections, and extensive molluscum contagiosum. In
addition, the patient had chronic EBV infection with persistent EBV
viremia (53 000 copies/mL at the age of 11 years) and positive anti–
EBNA-1 and anti-VCA IgG Ab. At the age of 5, patient F1P1 was
successfully treated for EBV Hodgkin B-cell lymphoma. The patient (now
17) is receiving Ig replacement therapy and anti-infective prophylaxis with
antibiotics and antivirals. Apart from lymphocytopenia, his blood counts
are consistently normal. A CT scan of the thymus performed at 11 years of
age was normal in appearance, structure, and size compared with age-
matched controls. He has no dysmorphic syndrome and his growth was
within the normal range.
Family F2 is consanguineous and of Turkish origin, with 3 children
affected (Figure 1A). Patients F2P1 and F2P2 developed recurrent bacterial
infections and eczema-like lesions of the skin beginning in the first years of
life, followed by recurrent pneumonitis and sinusitis associated with
bronchiectasis. Recurrent herpes simplex stomatitis was noted. At the age of
2 years, patient F2P1 had an episode of neutropenia (associated with
antinuclear and anticardiolipin Abs) that was treated with steroids and
azathioprine until the age of 7. Persistent EBV viremia (9000 copies/g
total DNA at the age of 9 years old) associated with detection of IgG Ab to
EBNA-1 and VCA was noted and was transiently accompanied by
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neutropenia. F2P1 developed EBV B-cell–lymphoproliferative syndrome
with multiple locations that was temporarily controlled by anti-CD20 Ab
therapy. She underwent hematopoietic stem cell transplantation (HSCT)
from an unrelated donor and died from GVHD and infectious complications
6 months later. Patient F2P2 also developed autoimmune hemolytic anemia
at the age of 1 year and displayed persistent EBV viremia (12 000
copies/mL at the age of 10 years) since that time. She was treated with
anti-CD20 Abs at the age of 11 and underwent HSCT (with her mother as
donor) at the age of 14.5 years. Persistent GVHD and infections led to death
5 months later.
Patient F2P3 had mild erythematous skin lesions and molluscum
contagiosum beginning in the first year of life. She was not infected with
EBV and after the initiation of prophylactic Ig and antibiotic therapy, no
other complications occurred until she received a T cell–depleted HSCT
from her haploidentical mother at the age of 4 years. Two years later, the
HSCT appears to have cured the immunodeficiency. At the age of 5, patient
F2P3 was found to have tricuspid valve insufficiency, together with
moderate right ventricular hypertrophy that has not progressed since then.
Patients F2P1, F2P2, and F2P3 did not display dysmorphic symptoms and
grew normally.
All patients and their parents gave their informed consent to participate
in the study in accordance with the Declaration of Helsinki. Data collection
and genetic studies were approved by the local independent ethics
committee and the French Advisory Committee on Data Processing in
Medical Research.
SNP analysis and sequence analysis
Single nucleotide polymorphism (SNP) and sequence analysis were as
described previously.7 Primers are listed in supplemental Table 1 (available
on the Blood Web site; see the Supplemental Materials link at the top of the
online article).
Gene expression analysis
Gene expression assays were performed as described previously.7 RT-PCR
was performed on each sample using MST1-specific primers (supplemental
Table 1). For comparative, real-time RT-PCR assays, ACTB (Hs99999903),
MST1 (Hs00178979), BCL2L11 (Hs01083836), BCL-2 (Hs99999018),
and KLF2 (Hs00360439) probes were labeled with 6-carboxy-fluorescein
dye (Applied Biosystems). The data were analyzed using the comparative
threshold cycle method and are presented as the relative change in gene
expression normalized against the calibrator sample corresponding to
control T cells.
Cells and cultures
PBMCs were isolated from blood samples taken from MST1-deficient
patients and controls. The MST1-deficient patients carried a homozygous
deletion or a homozygous nonsense mutation in MST1 with a predicted
early (F1P1-MST1: R117X) or late (F2P1-F2P2-F2P3-MST1: T1193fsX369)
premature stop codon. Phorbol 12-myristate 13-acetate (PMA)/ionomycin-
induced T lymphoblasts were obtained by incubating PBMCs for 72 hours
with PMA (40 ng/mL; Calbiochem), ionomycin (105 M; Calbiochem), and
IL-2 (40 IU/mL; Novartis) in Panserin medium (Biotech) supplemented
with 10% human AB serum (Etablissement Franc¸ais du Sang). More IL-2
(100 IU/mL) was added the cells were then cultured for 20 days in Panserin
medium with 5% human AB serum.
Immunoscope analysis
The SNP and sequence analysis were performed as described previously.8
Protein blots
Cell extracts and protein blots were prepared as described previously.7 Abs
against MST1 (Ab recognizing the aminoterminal region of human Mst1
protein), FOXO1, BCL2, and actin are described in supplemental Table 2.
The intensity of the immunoblot bands was quantified using ImageJ Version
1.4.3.67 Launcher Symmetry software.
Flow cytometry
Abs were purchased from eBioscience or BD Pharmingen; clone identifiers
are listed in supplemental Table 2. Standard flow cytometry methods
were used for staining cell-surface markers. Data were collected on a
FACSCanto II Version 6.1 (BD Biosciences) and analyzed with FlowJo
Version 8.8.4 software (TreeStar). Fluorescence intensities were quanti-
fied across experiments by normalizing the mean values obtained for each
patient against the mean values obtained for a control (set as 100%) in each
experiment or time point.
Apoptosis assay
The apoptosis assay was performed as described previously.9 Briefly,
PMA/ionomycin blasts were stimulated with 5-100 ng/mL of anti-CD95
Abs (APO-1.3).
Proliferation assays and cell-cycle analysis
Patient and control PBMCs (purified by density gradient centrifugation)
were cultured in medium alone or in the presence of PHA (5 g/mL) for
3 days in the presence of OKT3 (50 ng/mL) or ionomycin (105M) and
PMA (107M) for 4 days or with Ags such as Candida (50 g/mL;
Bio-Rad), tetanus toxoid (0125 lf/mL; Statens Serum Institute), and VZV
(Virion Institute, VZV 1191) for 6 days. [3H] thymidine was added for the
last 18 hours. Cell proliferation was determined as cpm of [3H] thymidine
incorporation.
Cell proliferation was monitored by labeling T cells with 10M CFSE
(Invitrogen) before stimulation with PMA/ionomycin according to the
manufacturer’s instructions. Every 24 hours, cells were harvested and the
CFSE dilution was assessed by flow cytometry.
Cell proliferation and cell-cycle analysis were determined by measuring the
incorporation of the nucleoside analog 5-ethynyl-2-deoxyuridine (EdU) into
newly synthesized DNA, according to the manufacturer’s instructions (Click-iT
EdU; Invitrogen). EdU incorporation was measured by the abundance of a
fluorescent product and sized on a FACSCanto flow cytometry system (BD
Biosciences) running FlowJo Version 8.8.4 software (TreeStar).
Detection of apoptotic cells with annexin V
The proportions of apoptotic, dead, and viable cells were determined using
the annexin V–PE Apoptosis Detection Kit I (BD Biosciences) according to
the manufacturer’s instructions. Cell fluorescence was measured analyzed
on the FACSCanto system running FlowJo Version 8.8.4 software.
Transwell migration assay
Chemotaxis assays using a 24-well Transwell (Costar; Corning) were
performed as described previously.10 Briefly, 5  105 PBMCs were loaded
into the upper chamber and allowed to transmigrate into the lower chamber
containing either 100 ng/mL of CCL19 (R&D Systems), 100 ng/mL of
CCL21 (R&D Systems), a 1:1 mixture of the 2 chemokines, or 1 g/mL of
SDF 1 for 3 hours at 37°C in 5% CO2. The cells that migrated to the lower
chamber were stained with cell-surface Abs for flow cytometry analysis.
The percentage migration was calculated by dividing the number of cells in
the lower chamber by the total cell input and multiplying the result by 100.
Ratios were calculating according to the initial number of CD4 T cells for
each individual. Chemotaxis data represent the average of triplicate wells in
duplicate experiments.
Accession codes
The GenBank reference sequence for MST1 mRNA is NM_006282. The
Protein Databank reference sequence for peptide MST1 is NP_006273.1.
Statistics
Results are expressed as the means 	 SD. Statistical analysis was per-
formed using a 2-tailed, unpaired Student t test. The threshold for
statistically significance was set to P 
 .05.
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Online supplemental material
Supplemental Figure 1 shows the immunoscope analysis of the TCR Vb
repertoire of 2 patients. Supplemental Figure 2 shows the result of
multipoint LOD scores analysis plotted along chromosome 20 containing
the MST1 gene. Supplemental Figure 3 shows the impaired expression of
CD127, CCR7, and CD62L by Mst1-deficient T cells, contrasting to the
normal expression of CD132. Supplemental Figure 4 shows impaired in
vitro chemotaxis of MST1–deficient CD4 T cells to CCL19 and CCL21
chemokines compared with normal migration in response to SDF1.
Supplemental Figure 5 shows the increase expression of Fas (CD95) at the
surface of MST1-deficient T cells. Supplemental Table 1 lists the primers
used to sequence Mst1 genomic DNA, and supplemental Table 2 lists the
Abs and labeled proteins used in this study.
Results
MST1 mutations are associated with a progressive T-cell
immunodeficiency
We studied 2 consanguineous unrelated families from Turkey in
which 4 individuals had been diagnosed with CIDs (Figure 1A and
Table 1). All 4 presented with recurrent bacterial and viral
infections, autoimmune manifestations, dermatitis, hypergam-
maglobulinemia G and A, and contrasting, defective Ab responses
(Table 1). Immunophenotyping with flow cytometry revealed that
all patients had progressive CD4 T-cell lymphopenia (Table 1)
characterized primarily by profoundly low naive CD4 T-cell counts
(Table 1 and Figure 1B). The frequency of CD8 T cells was close to
that of age-matched controls (Table 1). However, when subsets of
CD8 T cells were enumerated in 2 cases, a dramatic reduction in
naive (CD45RACCR7) CD8 T cells (Table 1) was observed
together with a lesser decrease in memory (CD45RACCR7)
CD8 T cells (data not shown). In one patient (F2P2), 80% of the
CD8 population expressed an effector-memory phenotype
(CD45RACCR7RIL-7), likely reflecting an in vivo expansion
of this population in a context of chronic viral infection. It is
noteworthy that a fraction of the T cells expressed HLA class II
molecules, which is an indication of in vivo activation (Table 1).
The patients’ B-cell counts were somewhat low, but their natural
killer cell counts were normal (Table 1). Immunoscope analysis of
T lymphocyte TCR V/ usage revealed an abnormal profile with
a small number of peaks; this indicates restricted heterogeneity of
TCR usage and/or clonal expansion (supplemental Figure 1). The
number of regulatory T cells, as assessed by Foxp3CD25hiCD4
coexpression, in 3 patients was decreased because of overall CD4
T-cell lymphopenia but was proportionally normal (Table 1).
Known causes of CIDs were excluded by genetic analysis (data
not shown). To determine the genetic basis of the immune disorder
in these families, we screened for homozygous chromosomal
regions by performing a genome-wide SNP analysis of DNA from
all 4 patients and their relatives (Figure 1A). This analysis revealed
a single region of 5.5 Mb on chromosome 20q13.12 compatible for
all markers with a multipoint analysis LOD score of 3.8 (supplemen-
tal Figure 2). Of the region’s 74 genes, 5 candidate genes were
sequenced prioritizing genes susceptible to being involved in the
hematopoietic system; of them, STK4/MST1 appeared to be an
interesting candidate because it is known to be expressed in the
lymphoid tissues and because its deficiency impairs T-cell function
in mice.11 STK4 was the only gene harboring mutations in patients.
Nucleotide sequencing of MST1 revealed a putative truncation
mutation in all 4 patients. One patient (F1P1) carries a homozygous
Figure 1. MST1 mutations in 2 families. (A) Pedigrees
of 2 families presenting a CID syndrome. Consanguinity
is indicated by double horizontal bars. Black boxes and
circles represent affected males and females, respec-
tively. Diagonal bar indicates deceased subjects. An
identification number was assigned to each patient.
(B) Semilogarithmic graph representing the progressive
CD4 T-cell lymphopenia (left) and the marked loss over
time of naive CD4 CD45RA T cells (right) observed in
MST1-deficient patients. (C) Schematic representation
of the MST1 protein. Mutations identified in the families
are indicated by arrows.
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349C  T nucleotide change in exon 4, resulting in a R117X
nonsense codon (Figure 1C). The 3 affected individuals from the
second family (patients F2P1, F2P2, and F2P3) carry a homozy-
gous, single-nucleotide deletion (T1103 del), which creates a
frameshift mutation at residue 368 and an immediately contiguous
nonsense codon (369X; Figure 1C). In both families, the parents
and siblings were found to be heterozygous for the mutated MST1
allele. The R117X mutation in family 1 affects the protein kinase
domain, whereas the 369X transition in family 2 is located in
MST1 regulatory domain downstream of the caspase3 cleavage site
and upstream of the Salvador/Rassf/Hippo (SARAH) domain12,13
(Figure 1C). These alleles are absent from ethnically matched
controls, dbSNP, and the 1000 Genomes Project database.
MST1 expression
We next analyzed the MST1 expression pattern using quantitative
real-time PCR on a panel of cDNAs from a wide range of
hematopoietic and nonhematopoietic tissues (Figure 2A). MST1
was found to be ubiquitously expressed in all tested tissues, with
the highest levels in hematopoietic tissues such as leukocytes and
spleen. In the mouse, it has been reported that the MST1
polypeptide and mRNA are 10-fold less abundant in wild-type
effector/memory CD4 T cells than in wild-type naive CD4
T cells.11 To determine whether MST1 is similarly regulated in
humans, we used quantitative, real-time PCR to analyze MST1
expression in naive and effector/memory CD4 and CD8 T-cell
subpopulations from healthy controls (Figure 2B). The abundance
of MST1 mRNA in control effector/memory CD4 and CD8 T cells
was half that observed in control naive CD4 and CD8 T cells
(Figure 2B).
We next assessed the impact of MST1 nonsense mutations on
the expression of MST1 mRNA and protein in patients’ lympho-
cytes. MST1 mRNA transcript expression was much lower in
MST1-deficient T cells than in control T cells (Figure 2C). MST1-
mutated proteins were not detected in cell lysates from patients
F1P1 or F2P3 relative to lysates from controls or heterozygous
Table 1. Immunological characteristics of patients F1P1, F2P1, F2P2, and F2P3
F1P1 F2P1 F2P2 F2P3
Age, y 16 9 11 3
Lymphocytes, /L  103 (normal range) 0.7 (1.4-3.3) 0.9 (1.9-3.7) 1.5 (1.9-3.7) 1.6 (2.3-5.4)
T-cell population (normal range)
CD3, /L  103 0.52 (1.0-2.2) 0.40 (1.2-2.6) 1.4 (1.2-2.6) 0.54 (1.4-3.7)
TCR/CD3, % (92-98) 54 99 87 94
TCR/CD3, % (2-8) 46 0.3 13 6
CD4, /L  103 0.13 (0.53-1.30) 0.10 (0.60-1.50) 0.16 (0.60-1.50) 0.24 (0.70-2.20)
CD8, /L  103 0.20 (0.33-0.92) 0.41 (0.37-1.10) 1.23 (0.37-1.10) 0.26 (0.49-1.30)
CD31CD45RA/CD4, % 1 (42-55) 2 (42-74) 2 (42-74) 31 (50-85)
Regulatory T cell CD4CD25, /L 4 (16-40)* ND 11 (80-130)† 37 (80-130)†
CD45RA/CD8, % 51 ( 61-91) 36 (63-92) 86 ( 63-92) 94 (69-97)
CD45RACCR7/CD8, % 1.3 (52-68) 1 (52-68) ND ND
CD45RACCR7/CD8, % 18 (16-28) 80 (16-28) ND ND
HLA-Class-II/CD3  10, % 49‡ ND 46‡ ND
T-cell proliferation, cpm  103 to:
Phytohemagglutinin (n  50) 4 ND 7 8
Anti-CD3 Ab (n  30) ND 0 5 13
PMA  ionomycin  IL2 (n  80) 12 ND 10 22
Candida Ag (n  10) 0.8 0.8 ND 16.5
Tetanus toxoid (n  10) 1 0.6 ND 19
Varicella zoster virus (n  10) ND 1.1 3.6 ND
B-cell population
B-lymphocyte (CD19), /L  103 (normal range) 0§ (0.11-0.57) 0.42 (0.27-0.86) 0.03 (0.27-0.86) 0.60 (0.39-1.40)
CD27/CD19 memory, % ND 1 ( 10) 13 ( 10) ND
Natural killer cells (normal range)
CD56CD16 per L  103 0.17 (0.10-0.48) 0.36 (0.10-0.48) 0.3 (0.10-0.48) 0.42 (0.13-0.72)
Ig levels, mg/mL (normal range)
IgM 0.37 (0.55-1.77) 
 0.17 (l0.68-1.28) 0.74 (0.54-1.53) 0.73 (0.54-1.53)
IgG 22.6 (4.8-14.) 20.5 (8.3-14.3) 15 (5.5-10.2) 14.3 (5.5-10)
IgA 2.19 (0.49-1.90) 10.9 (1.02-1.94) 3.24 (0.41-1.41) 1.74 (0.41-1.41)
IgE, U/mL 110 (10-100) 12 (10-100) ND ND
Allo-hemagglutinins titer IgG 1:32 ( 1:16) ND 1:4 ( 1:16) 1:256 ( 1:16)
Abs following immunization (normal range)
Anti-polio titer,  101 ( 40) 80/160/40 80/40/320  1280/64/64 ND
Anti-diphtheria toxoid, IU/mL ( 1) 
 0.1 ND ND ND
Anti-tetanus toxoid, IU/mL ( 0.5) 0.16¶ ND ND ND
Anti–Haemophilus influenzae ( 3 g/mL) 
 0.1 
 0.1¶ ND ND
Anti–Streptococcus pneumoniae ( 3 g/mL) ND 
 3¶ 
 3¶ ND
ND indicates not determined.
*CD127 low, CD25 high, CD4.
†CD25 high, CD4.
‡Moderate expression
§After anti-CD20 therapy.
¶Three months after vaccination in F1P1 and 6 weeks after vaccination plus previous infection in F2P1 and F2P2.
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subjects (Figure 2D). MST1 can be cleaved by caspases and the
cleaved form translocates to the nucleus.14 Because the mutation
identified in F2 patients is located downstream of the caspase
3 cleavage sites, it could still lead to the generation of a caspase-
cleaved active MST1 fragment constitutively present in the nucleus.
Therefore, we assessed the expression of the MST1 aminoterminal
protein fragment in nuclear lysates of the patients’ lymphoblasts.
MST1 protein was not detected in the cytoplasmic fraction or in
nuclear lysates (data not shown). These data indicate that this
newly observed immunodeficiency is associated with recessive,
loss-of-function/expression mutations in the MST1 gene.
Impaired proliferation and survival of MST1-deficient T cells
MST1-deficient patients had CD4 T-cell lymphopenia and mark-
edly reduced naive T-cell counts (Figure 1B). To further character-
ize the peripheral T-cell deficiency observed in MST1-deficient
patients, we assessed the proliferation response of the patients’
T cells to several stimuli. The MST1-deficient T cell proliferation
responses to Ags such as Candida, tetanus toxoid, and VZV and
mitogens such as anti-CD3 Ab or PHA were markedly impaired
(Table 1). Combination of PMA and ionomycin with IL-2 sup-
ported weak T-cell proliferation (Table 1). It is noteworthy that
T cells from the youngest patient (F2P3) had detectable Ag-
stimulated proliferation activity (Table 1).
To further investigate the proliferation potential of MST1-deficient
T cells, we labeled control and MST1-deficient PBMCs with CFSE
before PMA/ionomycin stimulation and sequentially assessed CD4 and
CD8 T-cell proliferation by CFSE dilution. At day 1, there was no
difference between the CFSE profiles of control and MST1-deficient
CD4 and CD8 T cells (Figure 3A). At day 3, most of the control CD4
and CD8 T cells had divided, as indicated by a decrease in CFSE
fluorescence (Figure 3A top). In contrast, a significant proportion of the
MST1-deficient CD4 and CD8 T cells still retained the dye, indicating
that these cells either had not divided or were dead (Figure 3A bottom).
To test the latter possibility, we examined apoptosis of the dividing
T cells (based on the ability to bind annexin V coupled to CFSE
staining). At all tested time points (days 1-5, Figure 3B), the proportion
of annexin V cells was markedly higher in the MST1-deficient T cells
Figure 2. MST1 expression. (A) MST1 transcript levels were quantified as the -fold difference of mRNA levels for MST1 normalized against the housekeeping gene ACTA1
(-actin). Data are representative of 2 independent experiments performed in duplicate. (B) MST1 transcript levels were quantified as the -fold difference in mRNA levels for
MST1 (normalized to ACTA1) in control sorted naive (CD4 CD45RA; CD8 CD45RA CCR7) and memory subpopulations of CD4 (CD4 CD45RO) and CD8 (CD8
CD45RO CCR7) T cells, as well as double-negative, double-positive, and single-positive thymocytes. Data are representative of 3 independent experiments performed in
duplicate. (C) MST1 transcript levels in control and patient T cells. Data are representative of 5 independent experiments performed in duplicate. (D) A Western blot analysis of
MST1 protein expression in lymphocytes from a healthy control, 2 heterozygous individuals (F2M, F1M), and 2 MST1-deficient patients with different homozygous nonsense
mutations. Actin was used as the loading control. Data are representative of 5 independent experiments.
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than in control T cells. This was confirmed by the absolute cell counts
(Figure 3C). The MST1-deficient T cells exhibited a high apoptosis rate
and thus a dramatic decrease in cell numbers between days 1 and
3 (Figure 3C). In contrast to control T cells, MST1-deficient T cells
showed a persistently high rate of apoptosis over time (Figure 3B). The
few MST-deficient annexin V CD4 and CD8 T cells showed no CFSE
dilution at day 3 and a limited dilution at day 4 (Figure 3D bottom),
whereas control CD4 and CD8 annexin V T cells had undergone 2 or
more divisions (Figure 3D top). A low but significant peak of dividing
MST1-deficient T cells was repeatedly observed at day 1 (Figure 3D
arrow), but not at later time points. These data indicate that MST1 is
essential for T-cell survival and that the overall reduction of the number
of dividing MST1-deficient T cells is essentially the consequence of an
accelerated apoptosis.
Further confirmation of the MST1-deficient CD4 T cells’ major
impairment in proliferation relative to control CD4 T cells was
provided by the low fraction of cells in the S phase (as measured by
EdU incorporation) and an accumulation of those in the G1 phase
(Figure 3E-F top). Similarly, MST1-deficient CD8 T cells prolifer-
ated less than control CD8 T cells (Figure 3E-F bottom). These
data suggest that in addition to MST1’s role in T-cell survival, the
protein could play a role in cell-cycle progression and therefore
T-cell proliferation.
The molecular consequences of MST1 deficiency
Given that the transcription factor Foxo1 is reportedly activated by
Mst1,15 and considering the critical function of Foxo1 in T cells
homeostasis,16,17 we investigated whether the FOXO1 protein
expression level was affected in MST1-deficient T cells. Indeed,
FOXO1 protein levels were much lower in patient cell lysates than
in control and heterozygous cell lysates (Figure 4A). These data
indicate that the interaction between MST1 and FOXO1 is
necessary for FOXO protein stability and expression in T cells.
In the mouse, Foxo1 has been found to control Il7R expression
in naive T cells.17 Therefore, we analyzed the T-cell surface
expression of IL-7R on various PBMC subsets. Compared with
control naive CD4 T cells, MST1-deficient naive CD4 CD45RA
T cells expressed significantly subnormal amounts of IL-7R
(CD127) protein (Figure 4B and supplemental Figure 3A left).
IL-7R expression was also much lower on effector/memory CD4
CD45RO T cells and absent on CD8 T cells (Figure 4B and
supplemental Figure 3A right). In contrast to the low expression of
IL-7R on MST1-deficient T-cell subpopulations, expression of
CD132 (the -chain receptor subunit of IL-7R that is shared with
other cytokine receptors) was not affected by the MST1 deficiency
(Figure 4C and supplemental Figure 3B). These observations
reveal a critical, specific role for MST1 in the control of IL-7R
expression. We were able to determine in vitro proliferation in the
presence of IL-7 once (with T cells from patient F1P1), but
adjunction of this interleukin did not enable cells to survive, as
measured by cell counts (data not shown).
Several studies in mice have reported that Foxo1 controls the
expression of L-selectin (CD62L) and the C-C chemokine receptor
type 7 (CCR7), 2 important homing receptors expressed on naive
CD4 and CD8 T cells.16,17 We therefore examined the expression of
CCR7 and CD62L on T cells isolated from control and MST1-
deficient patients. There was a consistent reduction in CCR7
expression in all MST1-deficient T-cell subpopulations relative to
levels in control T cells (Figure 4D and supplemental Figure 3C).
Further analysis of homing receptors revealed that CD62L expres-
sion was also dramatically lower in the patients’ naive CD4
CD45RA T cells than in control CD4 CD45RA T cells (Figure
4E and supplemental Figure 3D), as well as in the patients’
effector/memory CD4 CD45RO T cells (Figure 4E). Both L-
selectin and CCR7 expression are dependent on the activation of
the transcription factor Kruppel-like factor 2 (KLF2),18 through
direct binding of FOXO1 to the KLF2 promoter.19 We therefore
examined KLF2 mRNA expression in MST1-deficient T cells. The
assay results revealed markedly lower KLF2 mRNA expression in
PBMCs from MST1-deficient patients than in control PBMCs
(Figure 4F). The difference in lymphocyte subsets between control
and patient PBMCs may also account for the difference in the level
of transcript expression. These data show that MST1 deficiency
leads to impaired expression of the homing receptors CCR7 and
CD62L and likely in the transcription factor KLF2. These defects
could impair naive T-cell homing to secondary lymphoid organs,
because the chemotactic response to CCL19/CCL21 was impaired
in vitro (supplemental Figure 4).
MST1 deficiency is associated with increased FAS membrane
expression and FAS-induced apoptosis of T cells
The occurrence of massive apoptosis in freshly isolated MST1-deficient
T cells (Figure 5A left) and in response to stimulation with PMA/
ionomycin in vitro (Figure 3B), the progressive lymphopenia, and the
major loss of naive CD4 cells observed in vivo suggested that naive
T cells may undergo apoptosis after repetitive exogenous stimulations or
when exposed to stress signals. To further investigate MST1’s function
in T-cell apoptosis, we investigated the protein’s potential role in the
control of the death-receptor–induced apoptotic pathway by determin-
ing the sensitivity of MST1-deficient and control PMA/ionomycin–
activated lymphoblasts to FAS-mediated apoptosis. At doses of the
anti-CD95 (FAS) Ab Apo1.3 up to 20 ng/mL (Figure 5A right),
MST1-deficient lymphoblasts showed significantly higher apoptosis
levels than those observed in control T cells. Remarkably, all MST1-
deficient T-cell subsets expressed significantly higher amounts of
surface FAS than did control T cells (Figure 5B and supplemental
Figure 5). In particular, FAS expression was very high in MST1-
deficient naive CD4 CD45RA T cells compared with the low levels
seen in the corresponding control cells (Figure 5B and supplemental
Figure 5). These data show that FAS expression is up-regulated at the
surface of MST1-deficient T cells and can trigger cell apoptosis after cell
activation.
Because IL-7R signaling induces BCL2 expression,20 we investi-
gated whether MST1 deficiency, which is associated with low IL-7R
expression, impairs BCL2 expression. Indeed, BCL2 mRNA expres-
sion, as monitored by quantitative PCR, was found to be 3- to 5-fold
lower in MST1-deficient PBMCs (from F2P2 and F1P1, respectively)
than in control cells (Figure 5C). This relative decrease in BCL2 mRNA
expression level was correlated with low BCL2 protein expression in
MST1-deficient PBMC lysates compared with controls (Figure 5D).
These data indicate that MST1 is required to maintain BCL2 expression
and the survival of T cells in vivo.
These data highlight the impaired survival of MST1-deficient
T cells with an increase in cell apoptosis that is probably related to
defective IL-7R signaling and increased FAS expression/signaling.
Discussion
The present study reports a new primary T-cell immunodefi-
ciency associated with homozygous loss of function/expression
of the MST1-encoding gene, as observed in 4 patients from
2 families. Direct demonstration that MST1 mutations were
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Figure 3. Impaired proliferation and survival of MST1-deficient T cells in response to activation signals. (A) Control (Ctr.) and MST1-deficient (F2P2) CD4 and CD8
T cells were analyzed in terms of the rate of division (with CFSE dilution indicating cell proliferation) every 24 hours from day 1-3 after PMA/ionomycin–induced activation. Data
are representative of 4 independent experiments. (B) Cell death, as analyzed by annexin V binding to control (Ctr.) and MST1-deficient (F2P2) CD4 and CD8 T cells, at different
time points (every 24 hours) after CFSE labeling and PMA/ionomycin activation. Data are representative of 2 independent experiments. (C) Absolute cell counts for annexin V
T cells in the CFSE population presented in panel B. Data are representative of 3 independent experiments. (D) CFSE and annexin V staining of PMA/ionomycin-activated
control (Ctr.) and MST1-deficient (F2P2) CD4 and CD8 T cells. Cells were stained with annexin V and sized at different time points by flow cytometry. Histograms depict the
CFSE dilution of viable CD4 and CD8 T cells (annexin V). It is important to note that the CFSE graphs are normalized against the number of cells; the histograms represent
thepercentage of the maximum signal (% of Max) and do not reflect the number of dividing cells. Data are representative of 2 independent experiments. (E) Cell proliferation, as
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causal could not be provided, because the patient cells did not
survive attempted in vitro complementation of the defect.
However, the presence of nonsense mutations, the defective
expression of both MST1 mRNA (probably via nonsense-RNA–
mediated decay) and protein, and the phenotype’s similarity to
that of the mst1/ mouse all argue in favor of a causal link
between MST1 deficiency and the expressed immunodeficiency.
Remarkably, and although MST1 is ubiquitously expressed and
has been shown in mice to be involved in heart muscle size (at
least),21 no extralymphocytic defects were apparent. Possible
functional redundancy with MST2 function22,23 may account for
this observation. As observed in mice, MST1 expression was
highest in the patients’ naive T cells, a finding that strongly
suggests that MST1 has major role in this T-cell subset.
MST1 was first described in Drosophila as part of the Hippo
tumor-suppressor pathway24-26 that induces the transcriptional
coactivation of target genes involved in cell proliferation and
survival.24 The amino acid sequence of MST1 is highly conserved
in humans and mice. The serine-threonine kinase MST1 contains
an N-terminal catalytic domain, an autoinhibitory segment, and a
C-terminal coiled-coil SARAH domain that mediates hetero- and
homodimerization.27 MST1 is known to be involved in several
pathways controlling cell death,27-30 and its activity can be regu-
lated by caspase-induced cleavage, prompting translocation to the
nucleus and interaction with other proteins. In murine lympho-
cytes, the physiologic role of mst1 consists primarily of promoting
the survival and quiescence of naive T cells,11,31 egress from the
thymus, and homing to lymphoid organs.10,32 Indeed, mst1/ mice
display an accumulation of mature lymphocytes in the thymus, loss
of naive T cells, and depletion of lymphoid organs. In humans, the
MST1-FOXO1 activation pathway likely mediates these functions,
at least in part. The FOXO transcription factors represent one of
several classes of functionally relevant MST1 substrates.17,33,34
Our present findings show that MST1 also has a key role in the
maintenance and homing of human naive T cells. The importance
of the role of MST1 in cell survival is emphasized by the severe in
vivo loss of naive T cells (both CD4 and CD8 T cells) over time
and the dramatic in vitro cell death of activated cells. Defective
expression of IL-7R and anti-apoptotic BCL2 molecules may
account for this finding (at least in part). MST1 deficiency also
results in loss of FOXO1, a pivotal intermediate in the defective
expression of IL-7R, the homing receptors CCR7 and CD62L,
and their triggering transcription factor KLF2.16,18,19 In addition,
the increased number of CD8 T cells (but not CD4) with low
expression of IL-7R, CCR7, and CD62L associated with high
expression of Fas evidenced in 1 patient may also reflect the
expansion of “exhausted” (or terminally differentiated) effector-
memory T cells in the context of chronic viral infections.35,36 The
restricted TCR repertoire observed in Mst1-deficient patients likely
reflects the expansion of a limited number of effector clones in this
environmental context. MST1 deficiency may also impair the
development and/or maintenance of regulatory T cells, the absolute
number of which was decreased in the patients, an observation that
might be related to the advent of autoimmune manifestations in
2 patients. Naive T cells from mst1/ mice were reported to
proliferate strongly in response to TCR/CD3 stimulation. Unfortu-
nately, we were unable to test or confirm this result when using
T cells isolated from MST1-deficient patients because most of
them (3 of 4) had no more naive T cells in the periphery.
Interestingly, T cells isolated from the youngest patient still
harboring a low number of naive T cells exhibited a detectable
proliferation after PMA/ionomycin and Ag stimulation.
It has been proposed recently that naive T-cell quiescence in
mice is an active phenomenon based on the balance between Foxo1
and Foxp1 transcription factor activities.37 In contrast to Foxo1,
Foxp1 down-regulates IL-7R expression. An MST1 deficiency
would lower FOXO1 expression and allow the activity of FOXP1
to continue unimpeded. Cytokine-based or TCR triggering is likely
to induce T-cell activation at a lower threshold in this context
because the MST1-based barrier to activation is no longer present.
In this respect, our findings that MST1-deficient naive T cells
overexpress FAS and exhibit an early, transient peak (day 1) of
proliferation ex vivo are consistent with in vivo activation of the
naive T-cell pool in the absence of MST1. This activation state may
contribute to cell death through increased FAS-mediated apoptosis,
as seen here, although other cell death pathways may have a role. It
remains to be seen whether the observed premature cell death of
naive T cells is also related to MST1-induced changes in the
expression of SOD2 and catalase-2 enzymes that neutralize the
reactive oxygen species generated by cell stress.38,39 It is therefore
conceivable that MST1 plays a central, orchestrating role in
maintaining naive T cells by preventing the activation of a range of
cell death pathways.
The present study describes a new primary T-cell immunodeficiency
with fairly severe phenotypic consequences that are characterized by
recurrent bacterial and viral infections and autoimmune manifestations.
Faulty control of EBV replication is a constant feature in B-cell
lymphoproliferation and Hodgkin lymphoma, as observed in other
severe forms of T-cell immunodeficiency.40,41 Therefore, the mechanism
underlying the defective maintenance of naive T cells in MST1 defi-
ciency probably differs from those described in known impairments in
T-cell differentiation (eg,c, JAK3, Rag-1, Rag-2, andArtemis deficien-
cies)1,2 or T-cell activation (eg, ZAP-70, ORA-1, STIM-1, ITK, or
DOK-8 deficiencies).1,2,5,42 MST1 deficiency phenotype shares similar
findings with DOCK8 deficiency, which include susceptibility to viral
infections, T-cell lymphopenia, and reduced in vitro T-cell prolifera-
tion.5,43-45 Nevertheless, there are also significant phenotypic differences
that predominantly consist in reduced naive CD8 T-cell counts, pre-
served CD4 T-cell proliferation, eosinophilia, and marked atopy that are
observed in DOCK8 deficiency only.43 Furthermore, it may be that other
T-cell immunodeficiencies characterized by a selective reduction in the
naive T-cell subset will help to determine the roles of other important
molecules required for human T-cell maintenance and control of viral
replication and reactivity to self.
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Figure 4. Down-regulation of FOXO1, IL-7R, CCR7, and CD62L expression in MST1-deficient T cells. (A) Left: Western blot showing FOXO1 and MST1 protein level in
whole-lymphocyte lysates from a healthy control, 2 heterozygous patients (patients F2M and F1M), and 2 MST1-deficient patients with different homozygous nonsense
mutations (patients F1P1 and F2P3). Actin served as a loading control. Right: Abundance of FOXO1 relative to actin (signal intensity measurement). Results are presented as
the FOXO1/actin ratio (in arbitrary units). Data are representative of 3 independent experiments. (B-C) IL-7R (CD127) and common cytokine receptor -chain (CD132)
expression on CD3, CD8, CD4, CD4 CD45RA, and CD4 CD45RO T cells from a control and an MST1-deficient patient (F2P2). Similar results were obtained for cells from
F1P1. One of 6 experiments with similar results is shown (4 independent experiments for F2P2 and 2 for F1P1). (D-E) CCR7 and CD62L expression by freshly isolated control
and MST1-deficient (F2P2) PBMCs. One of 6 experiments with similar results is shown (4 independent experiments for F2P2 and 2 for F1P1). (F) Quantitative PCR analysis of
KLF2 mRNA expression. KLF2 transcript levels were quantified as the -fold difference normalized against ACTA1 (-actin) mRNA levels in control (Ctr.) and MST1-deficient
(F1P1 and F2P2) PBMCs.
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Figure 5. Greater expression of FAS is correlated with greater sensitivity to FAS-induced apoptosis and down-regulation of BCL2 expression in MST1-deficient
T cells. (A) Spontaneous apoptosis (left) and death-receptor–induced apoptosis (right) in vitro was assessed on PMA/ionomycin–activated T cells from control (Ctr.) and
MST1-deficient patients (patients F1P1 and F2P2). After 8 days of activation, blasts were incubated overnight in the absence or presence of a dose gradient of anti-FAS Ab
(Apo1.3). The percentage of apoptotic cells (means 	 SEM of 3 independent experiments) was then measured by propidium iodide labeling of DNA fragmentation. *P 
 .05;
**P 
 .01. (B) FAS expression on PBMCs freshly isolated from control (Ctr.) and MST1-deficient patients (patients F1P1 and F2P2). FAS expression was monitored in a freshly
isolated T-cell subpopulation. One of 6 experiments with similar results is shown. (C) Quantitative PCR analysis of BCL2 mRNA expression normalized against ACTA1 (-actin)
mRNA in total PBMCs freshly isolated from control (Ctr.) and MST1-deficient patients (patients F1P1 and F2P2). Data represent the means of 4 independent experiments.
(D) Western blot showing BCL2 and MST1 protein levels in whole lymphocytes lysates from a healthy individual and an MST1-deficient patient (patient F1P1). Actin served as
the loading control.
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